Interv Akut Kardiol. 2009;8(1):28-33

Practical guidelines for pharmacologic atrial fibrillation treatment

Petr Heinc
I. interní klinika FN a LF UP Olomouc

Atrial fibrillation is the most worldwide-sustained arrhythmia and independent risk factor for thromboembolic stroke. Treatment strategy

and guidelines for pharmacologic approaches for control of rhythm, control of frequency and thromboembolic prevention are

presented.

Keywords: atrial fibrillation – risk factors, strategy of pharmacological treatment, control of rhythm, control of frequency, thromboembolic prevention.

Published: April 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Heinc P. Practical guidelines for pharmacologic atrial fibrillation treatment. Interv Akut Kardiol. 2009;8(1):28-33.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Lévy S, Breithardt G, Campbell RWF, et al. Atrial fibrillation: current knowledge and recommendations for management. Eur Heart J 1998; 19: 1294-1320. Go to original source... Go to PubMed...
    2. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-Up Study: Am J. Med 1995; 98: 476-484. Go to original source... Go to PubMed...
    3. Olshansky B, Rosenfeld LE, Warner AL, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004; 43: 1201-1208. Go to original source... Go to PubMed...
    4. Hagens VE, Ranchor AV, Van SE, et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol 2004; 43: 241-247. Go to original source... Go to PubMed...
    5. Sherman DG, Kim SG, Boop BS, et al. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. Arch Intern Med 2005; 165: 1185-1191. Go to original source... Go to PubMed...
    6. Pedersen OD, Bagger H, Kober L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100: 376-380. Go to original source... Go to PubMed...
    7. Komatsu T, Nakamura S, Suzuki O, et al. Long-term efficacy of combination therapy using antiarrhythmic agents and angiotensin converting enzyme inhibitor in patients with paroxysmal and persistent atrial fibrillation: importance of the timing of administration. J Cardiol 2003; 41: 73-80.
    8. Healey JS, Baranchuk A, Crystal E et al. Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. A Meta-Analysis. J Am Coll Cardiol 2005; 45:1832-1839. Go to original source... Go to PubMed...
    9. Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003; 92: 1343-1345. Go to original source... Go to PubMed...
    10. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109: III39-III43. Go to original source... Go to PubMed...
    11. Azpitarte J, Alvarez M, Baun O, et al. Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study. Eur Heart J 1997; 18: 1649-1654. Go to original source... Go to PubMed...
    12. Klein AL, Grim RA, Tseva IW, et al. Cardioversion guided by transesophageal echocardiography: the ACUTE Pilot Study: a randomized, controlled trial Assessment of Cardioversion Using Transesophageal Echocardiography. Ann Int Med 1997; 126: 200-209. Go to original source... Go to PubMed...
    13. Suttorp MJ, Kingma JH, Jessurun ER, Lie AII, van Hemel NM, Lie KI. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 1990; 16: 1722-1727. Go to original source... Go to PubMed...
    14. Lukl J, Řezáčová M, Černošek B, et al. Užití amiodaronu v léčbě míhání síní odolného proti digoxinu. I. Schopnost amiodaronu převést míhání síní na sinusový rytmus a jeho krátkodobé udržení. Vnitř Lék 1985; 31: 177-181. Go to PubMed...
    15. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Europace 2006; 8: 651-745. Go to original source... Go to PubMed...
    16. Kochiadakis GE, Igoumenidis NE, Parthenakis FI, et al. Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol 1999; 33: 966-971. Go to original source... Go to PubMed...
    17. Letelier LM, Udol K, Ena J, et al. Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a metaanalysis. Arch Intern Med 2003; 163: 777-785. Go to original source... Go to PubMed...
    18. Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol 2001; 37: 542-547. Go to original source... Go to PubMed...
    19. Di Benedetto S. Quinidine versus propafenone for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1997; 80: 518-519. Go to original source... Go to PubMed...
    20. Boriani G, Biffi M, Capucci A, et al. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized, controlled trial. Ann Intern Med 1997; 126: 621-625. Go to original source... Go to PubMed...
    21. Kay GN, Ellenbogen KA, Giudici M, et al. The Ablate and Pace Trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. APT Investigators. J Interv Card Electrophysiol 1998; 2: 121-135. Go to original source... Go to PubMed...
    22. Weerasooriya R, Davis M, Powell A, et al. The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial (AIRCRAFT). J Am Coll Cardiol 2003; 41: 1697-1702. Go to original source... Go to PubMed...
    23. Anderson JL, Prystowsky EN. Sotalol: an important new antiarrhythmic. Am Heart J 1999; 137: 388-409. Go to original source... Go to PubMed...
    24. Agarwal AK, Venugopalan P. Beneficial effect of carvedilol on heart rate response to exercise in digitalised patients with heart failure in atrial fibrillation due to idiopathic dilated cardiomyopathy. Eur J Heart Fail 2001; 3: 437-440. Go to original source... Go to PubMed...
    25. Lundstrom T. Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil. J Am Coll Cardiol 1990; 16: 86-90. Go to original source... Go to PubMed...
    26. Tamariz LJ, Bass EB. Pharmacological rate control of atrial fibrillation. Cardiol Clin 2004; 22: 35-45. Go to original source... Go to PubMed...
    27. Farshi R, Kistner D, Sarma JS, et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol 1999; 33: 304-310. Go to original source... Go to PubMed...
    28. Clemo HF, Wood MA, Gilligan DM, et al. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol 1998; 81: 594-598. Go to original source... Go to PubMed...
    29. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
    30. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 1999; 30: 1223-1229. Go to original source... Go to PubMed...
    31. Gorter JW. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFf) study groups. Neurology 1999; 53: 1319-1327. Go to original source... Go to PubMed...
    32. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The European Atrial Fibrillation Trial Study Group. N Engl J Med 1995; 333: 5-10.
    33. The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators. Arch Intern Med 1997; 157: 1237-1240.
    34. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: 64S-94S. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.